Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00998933 · ClinicalTrials.gov registry record · Phase 1
Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure
A Phase 1 study of Hypogonadism, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00998933 is a Phase 1 study of Hypogonadism that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 24 participants, below the 119-participant average among 21 other Hypogonadism trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00998933, a Phase 1 study of Hypogonadism, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
To further characterize the transfer potential of marketed testosterone gel and new 1.62% formulation.
Conditions Studied
Interventions
- DRUG Testosterone gel 1.62%
Study Locations (1)
Florida
- Site 1 - Miami Gardens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00998933
The ClinicalTrials.gov registry entry for NCT00998933 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 21 other Hypogonadism trials with a reported enrollment target (80% lower). The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which Testosterone gel 1.62% is the first listed.
NCT00998933 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00998933 about?
NCT00998933 is a clinical study titled "Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure". To further characterize the transfer potential of marketed testosterone gel and new 1.62% formulation.
What is the current status of trial NCT00998933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-10. Estimated completion is 2009-10.
What conditions does trial NCT00998933 study?
This clinical trial studies the following conditions: Hypogonadism.
What interventions are being tested in trial NCT00998933?
The interventions under investigation include: Testosterone gel 1.62% (DRUG).
Who is sponsoring clinical trial NCT00998933?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00998933 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
ACTIVE NOT RECRUITING · Phase 1
-
ORAL T-6: Oral Androgens in Man-6
COMPLETED · Phase 1
-
Observation of Environment and Reproductive-Endocrine Effects
RECRUITING
-
Adaptions and Resiliency to Multi-Stressor OpeRations
RECRUITING · Phase 4
-
Inherited Reproductive Disorders
RECRUITING
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.